Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 3,101–3,200 of 15,747
Advancements in monkeypox vaccines development: a critical review of emerging technologies
Garcia-Atutxa, I., Mondragón‐Terán, P., Saquero, A. H., & Villanueva‐Flores, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456060 · Cited by 50
Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients
Tsapepas, D. S., Paget, K., Mohan, S., Cohen, D. J., & Husain, S. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.05.004 · Cited by 36
“08% incidence after completion of the primary vaccination series.(1-3) Our data indicate a 0.”
COVID-19 vaccines and thrombosis with thrombocytopenia syndrome
Lai, C., Ko, W., Chen, C., Chen, P.-Y., Huang, Y., Lee, P., & Hsueh, P. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1949294 · Cited by 42
Shrotri, M., Fragaszy, E., Geismar, C., Nguyen, V. G., Beale, S., Braithwaite, I., Byrne, T., Fong, W. L. E., Kovar, J., Navaratnam, A. M. D., et al. (2021) · medRxiv · doi:10.1101/2021.05.12.21257102 · Cited by 35
Intentions of public school teachers in British Columbia, Canada to receive a COVID-19 vaccine
Racey, C. S., Donken, R., Porter, I., Albert, A., Bettinger, J. A., Mark, J., Bonifacio, L., Dawar, M., Gagel, M., Kling, R., et al. (2021) · Vaccine X · doi:10.1016/j.jvacx.2021.100106 · Cited by 36
Impact of January 2021 curfew measures on SARS-CoV-2 B.1.1.7 circulation in France
Domenico, L. D., Sabbatini, C. E., Pullano, G., Lévy-Bruhl, D., & Colizza, V. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.15.2100272 · Cited by 42
Raw, R. K., Kelly, C. A., Rees, J. C., Wroe, C., & Chadwick, D. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.05.035 · Cited by 41
Menni, C., May, A., Polidori, L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3980542 · Cited by 34
Shrotri, M., Krutikov, M., Palmer, T., et al. (2021) · medRxiv · doi:10.1101/2021.03.26.21254391 · Cited by 52
Kitro, A., Sirikul, W., Dilokkhamaruk, E., Sumitmoh, G., Pasirayut, S., Wongcharoen, A., Panumasvivat, J., Ongprasert, K., & Sapbamrer, R. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100182 · Cited by 35
“7% experienced systemic side effects such as fever, tiredness, and headache that resolved in one to two days [7,10].”
Strategic and Chemical Advances in Antibody–Drug Conjugates
Alradwan, I. A., Alnefaie, M. K., Fayez, N. A., Aodah, A. H., Majrashi, M. A., Alturki, M., Fallatah, M., Almughem, F. A., Tawfik, E. A., & Alshehri, A. A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091164 · Cited by 49
Kast, F., Klein, C., Umaña, P., Gros, A., & Gasser, S. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1869389 · Cited by 36
Regulation of endogenous cardiomyocyte proliferation: The known unknowns
Secco, I., & Giacca, M. (2023) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2023.04.001 · Cited by 37
Man, M. A., Rosca, D., Bratosin, F., Firă-Mladinescu, O., Ilie, A. C., Burtic, S.-R., Fildan, A. P., Fizedean, C. M., Jianu, A. M., Negrean, R. A., et al. (2024) · Vaccines · doi:10.3390/vaccines12020189 · Cited by 37
Revolutionizing medicine with toll-like receptors: A path to strengthening cellular immunity
Malik, J. A., Kaur, G., & Agrewala, J. N. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127252 · Cited by 36
Wang, X., Haeussler, K., Spellman, A., Phillips, L. E., Ramiller, A., Bausch-Jurken, M. T., Sharma, P., Krivelyova, A., Vats, S., & de Velde, N. V. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1204831 · Cited by 32
“participating in pivotal trials of mRNA-1273 and BNT162b2 (5; 6).”
BackgroundHuman IgG and IgA responses to COVID-19 mRNA vaccines
(2021) · doi:10.1101/2021.03.23.21254060 · Cited by 34
Nickel, O., Rockstroh, A., Wolf, J., Landgraf, S., Kalbitz, S., Kellner, N., Borte, M., Pietsch, C., Fertey, J., Lübbert, C., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263861 · Cited by 35
“Currently available vaccines were designed on the basis of the ancestral sequence of SARSCoV-2 and have shown to elicit durable and potent immune responses to prevent from severe COVID-19 [6,7].”
BackgroundBNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Roest, S., Hoek, R. A. S., & Manintveld, O. C. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104281 · Cited by 88
Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2
Wang, Y.-T., Long, X., Ding, X., Fan, S.-R., Cai, J., Yang, B.-J., Zhang, X., Luo, R., Yang, L., Ruan, T., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113966 · Cited by 36
Groner, J., Göpferich, A. M., & Breunig, M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.034 · Cited by 37
Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
He, W., Yuan, M., Callaghan, S., Musharrafieh, R. G., Song, G., Silva, M., Beutler, N., Lee, W.-H., Yong, P., Torres, J. L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl9605 · Cited by 32
Pedrazini, M. C., & da Silva, M. H. (2021) · Dermatologic Therapy · doi:10.1111/dth.15129 · Cited by 37
“What has been observed is that these vaccines have shown adverse effects in some people and among them are pain at the injection site, fever, headache, nausea and vomiting.(1,2) In some individuals”
BackgroundNanovaccines against Viral Infectious Diseases
Heng, W. T., Yew, J. S., & Poh, C. L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122554 · Cited by 42
Chansaenroj, J., Yorsaeng, R., Puenpa, J., Wanlapakorn, N., Chirathaworn, C., Sudhinaraset, N., Sripramote, M., Chalongviriyalert, P., Jirajariyavej, S., Kiatpanabhikul, P., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267102 · Cited by 41
Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines
Abbasi, S., & Uchida, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050644 · Cited by 36
In Gratitude for mRNA Vaccines
Stuart, L. M. (2021) · New England Journal of Medicine · doi:10.1056/nejmcibr2111445 · Cited by 36
Vaquero, S. T., de Campos‐Mata, L., Ramada, J. M., Díaz, P., Navarro‐Barriuso, J., Ribas‐Llauradó, C., Melero, N. R., Carolis, C., Cerutti, A., Gimeno, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737083 · Cited by 39
Vignier, N., Brureau, K., Granier, S., Breton, J., Michaud, C., Gaillet, M., Agostini, C., Ballet, M., Nacher, M., Valdes, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9060682 · Cited by 39
“When the preliminary results on the efficacy of the vaccine BNT162b were published in December 2020, Europe, including France, implemented free vaccination campaigns [3].”
BackgroundPiccolo, V., Bassi, A., Argenziano, G., Mazzatenta, C., Cutrone, M., Neri, I., Grimalt, R., & Russo, T. P. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17320 · Cited by 33
Maintenance and functional regulation of immune memory to COVID-19 vaccines in tissues
Davis‐Porada, J., George, A. B., Lam, N., Caron, D. P., Gray, J. I., Huang, J., Hwu, J., Wells, S. B., Matsumoto, R., Kubota, M., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.10.003 · Cited by 44
Corma‐Gómez, A., Fernández‐Fuertes, M., García, E., Fuentes, A. P., Gómez‐Ayerbe, C., Rivero‐Juárez, A., Domínguez, C. B., Santos, M., Viñuela, L., Palacios, R., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.05.018 · Cited by 35
Digital herd immunity and COVID-19
Bulchandani, V. B., Shivam, S., Moudgalya, S., & Sondhi, S. L. (2021) · Physical Biology · doi:10.1088/1478-3975/abf5b4 · Cited by 42
Selvaraj, G., Kaliamurthi, S., Peslherbe, G. H., & Wei, D. (2021) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-021-00438-3 · Cited by 37
“Likewise, mRNA-1273 vaccine components include the spike glycoprotein of SARS-CoV-2 coding mRNA, PEG 2000 dimyristoyl glycerol, 1,2-distearoyl-sn-glycero3-phosphocholine, cholesterol, SM-102, tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate, and sucrose.”
InfluentialEvidence-Based Policies in Public Health to Address COVID-19 Vaccine Hesitancy
Chirico, F., & da Silva, J. A. T. (2023) · Future Virology · doi:10.2217/fvl-2022-0028 · Cited by 47
“However, the opinions of reputable scholars are not enough, and the public requires tangible evidence to affect a potentially life-saving decision, so robust, evidence-based clinical trial-derived data may convince some vaccination-hesitant individuals that mRNA vaccines are effective and safe [23], the latter being a…”
BackgroundRogers, J. H., Cox, S. N., Hughes, J. P., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.026 · Cited by 34
“Available vaccines report high efficacy and safety [11,12], and the U.”
Li, Y. K., Lui, M. P. K., Lip, L. Y., et al. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.589 · Cited by 35
“The Pfizer‐BioNTech Comirnaty is a newer mRNA vaccine in which safety have been demonstrated by multinational placebo‐controlled, observer‐blinded, pivotal efficacy trials.(17) However, similar data in Asian populations is limited.”
BackgroundThe association between COVID-19 vaccination and Bell's palsy
Cirillo, N., & Doan, R. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00467-9 · Cited by 42
Safety and immunogenicity of inactivated COVID‐19 vaccine in health care workers
Benjamanukul, S., Traiyan, S., Yorsaeng, R., Vichaiwattana, P., Sudhinaraset, N., Wanlapakorn, N., & Poovorawan, Y. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27458 · Cited by 38
The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccinesPreprint
Liu, Y., Arase, N., Kishikawa, J.-I., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.22.457114 · Cited by 33
“Cryo-EM analysis of the Delta spike All anti-NTD monoclonal neutralizing antibodies from COVID-19 patients failed to bind to Delta spike whereas most of the enhancing antibodies maintained reactivity to Delta spike (Figure 1A).”
BackgroundInfluentialAn overview of lipid constituents in lipid nanoparticle mRNA delivery systems
Wu, S., Lin, L., Shi, L., & Liu, S. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1978 · Cited by 41
COVID-19 Vaccine-Related Psychological Stress Among General Public in China
Zheng, Y., Sun, J., Liu, L., Zhao, Y., Yan, W., Yuan, K., Su, S., Lu, Z.-A., Huang, Y., Liu, L., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.774504 · Cited by 39
“rural), education attainment, marital status, andmonthly family income, history of chronic diseases, history of mental disorders, and family history of mental disorders; (2) experiences related to the COVID-19 epidemic, including suspect or confirmed infection, infection status of family members or friends, participat…”
Backgroundvan Vliet, V. J. E., Huynh, N., Palà, J., Patel, A., Singer, A. U., Slater, C., Chung, J., van Huizen, M., Teyra, J., Miersch, S., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1011065 · Cited by 38
“Even though vaccines against SARS-CoV-2 were quickly developed and have great efficacy against severe disease [32,33], a certain part of the population will be unable to receive such a prophylaxis due to, for example, being immunocompromised or being too young to be immunized.”
BackgroundTrained immunity-inducing vaccines: Harnessing innate memory for vaccine design and delivery
Baydemir, İ., Dulfer, E. A., Netea, M. G., & Domínguez‐Andrés, J. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.109930 · Cited by 45
González, S. E., Olszevicki, S., Gaiano, A., Baino, A. N. V., Regairaz, L., Salazar, M. R., Pesci, S. A., Marín, L., González, V., Varela, T., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100316 · Cited by 38
Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination
Ooi, E. E., Dhar, A., Petruschke, R. A., Locht, C., Buchy, P., & Low, J. G. H. (2022) · npj Vaccines · doi:10.1038/s41541-022-00453-5 · Cited by 42
Alshehry, Y., Liu, X., Zhang, Y., & Zhu, G. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113617 · Cited by 39
Mekonnen, B. D., & Mengistu, B. A. (2022) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2022.101001 · Cited by 37
Brumfiel, C. M., Patel, M. H., DiCaudo, D. J., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1924371 · Cited by 34
“3% of Pfizer-BioNTech vaccine recipients in the phase 2/3 trial data and was attributed to robust immune responses elicited by the vaccine [2].”
BackgroundZhang, Q., Wang, M., Han, C., Wen, Z., Meng, X., Qi, D., Wang, N., Du, H., Wang, J., Lu, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11030673 · Cited by 39
“Compared with other vaccine technology platforms, the mRNA vaccine platform also has advantages, including 1) A short R&D cycle; 2) Convenient large-scale production [11,12]; 3) No risk of infection or genome integration [13–15]; 4) The human expression system expresses antigens with good immunogenic recovery [16]; 5)…”
BackgroundBaruchel, A., Bertrand, Y., Boissel, N., Brethon, B., Ducassou, S., Gandemer, V., Domenech, C., Leblanc, T. M., Leverger, G., Michel, G., et al. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.04.003 · Cited by 36
Minor Intron Splicing from Basic Science to Disease
Marabti, E. E., Malek, J. A., & Younis, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116062 · Cited by 38
“The evidence for this 50 year old theory has grown over the years, and the importance of RNA has grown with it, giving rise to new fields in RNA biology that have expanded toward medical/clinical applications, including experiments done in the early 1990s showing protein production from an mRNA injected into mice skel…”
BackgroundLong-term effect of SARS-CoV-2 infection on cardiovascular outcomes and all-cause mortality
Aleksova, A., Fluca, A. L., Gagno, G., Pierri, A., Padoan, L., Derin, A., Moretti, R., Noveska, E. A., Azzalini, E., D’Errico, S., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121018 · Cited by 41
Cultural competence in covid-19 vaccine rollout
Hanif, W., Ali, S. N., Patel, K., & Khunti, K. (2020) · BMJ · doi:10.1136/bmj.m4845 · Cited by 33
Lin, S., Lau, L. H. S., Chanchlani, N., Kennedy, N. A., & Ng, S. C. (2022) · Gut · doi:10.1136/gutjnl-2021-326784 · Cited by 37
Liu, J., Xu, K., Xing, M., Zhuo, Y., Guo, J., Du, M., Wang, Q. M., An, Y., Li, J., Gao, P., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00360-4 · Cited by 35
Takeuchi, J. S., Fukunaga, A., Yamamoto, S., Tanaka, A., Matsuda, K., Kimura, M., Kamikawa, A., Kito, Y., Maeda, K., Ueda, G., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19581-y · Cited by 36
Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review.
SeyedAlinaghi, S., Karimi, A., Pashaei, Z., Afzalian, A., Mirzapour, P., Ghorbanzadeh, K., Ghasemzadeh, A., Dashti, M., Nazarian, N., Vahedi, F., et al. (2022) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v10i1.1597 · Cited by 33
“12%) among 803 participants who had received Pfizer (20), and one case of leg paresthesia in a 2nd-phase RCT of Pfizer vaccine (29).”
BackgroundMyocarditis associated with COVID-19 and its vaccines - a systematic review
Rout, A., Suri, S. S., Vorla, M., & Kalra, D. K. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.10.004 · Cited by 42
“The two common vaccines commercially available in 2021 in the USA were both mRNA vaccines - BNT162b2 (Pfizer) and mRNA-1273 (Moderna) and are highly effective and safe.(11,12) A third vaccine, manufactured by Janssen had a recombinant, replicationincompetent adenovirus type 26 expressing the SARS-CoV-2 spike protein,…”
BackgroundCovid-19 vaccine and its consequences in pregnancy: Brief review
Leik, N. K. O., Ahmedy, F. B., Guad, R. M., & Baharuddin, D. M. P. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.103103 · Cited by 38
“It should be noted that unpleasant responses and adverse events affect both expectant mothers and non-pregnant women [15].”
Hodel, K. V. S., Fiuza, B. S. D., Conceição, R. S., Aleluia, A. C. M., Pitanga, T. N., Fonseca, L. M. D. S., Valente, C. O., Rezende, C. S. M. E., & Machado, B. A. S. (2024) · Pharmaceuticals · doi:10.3390/ph17060807 · Cited by 56
“Recently, for the COVID-19 vaccine, in addition to the common effects, some individuals have reported more serious side effects, including allergic reactions, myocarditis (inflammation of the heart muscle), and thrombosis (blood clot formation) [192,193].”
BackgroundCOVID-19, Vaccines, and Thrombotic Events: A Narrative Review
Abrignani, M. G., Murrone, A., Luca, L. D., Roncon, L., Lenarda, A. D., Valente, S., Caldarola, P., Riccio, C., Oliva, F. G., Gulizia, M. M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040948 · Cited by 40
“Gam-COVID-Vac (Sputnik V) Gamaleya Institute (Moscow, Russia) Adenovirus vector Ad26 and Ad5 CoV2-S ConvideciaTM CanSino Bio (Tianjin, China) Adenovirus vector Ad5-nCoV CoronaVac Sinovac Biotech (Beijing, China) Inactivated virus BBIBP-CorV Beijing Institute of Biological Products(Beijing, China) Inactivated virus The…”
BackgroundInfluentialThe mRNA Vaccine Technology Era and the Future Control of Parasitic Infections
You, H., Jones, M. K., Gordon, C. A., Arganda, A. E., Cai, P., Al-Wassiti, H., Pouton, C. W., & McManus, D. P. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00241-21 · Cited by 46
Zhang, G. F., Meng, W., Chen, L., Ding, L., Feng, J., Pérez, J., Ali, A., Sun, S., Liu, Z., Huang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28032 · Cited by 35
“S, which have since contributed to the control of the pandemic.(32,34,44) While Ad26.”
Background(2021) · doi:10.1101/2021.04.14.21255431 · Cited by 62
“In clinical trials and subsequent observational studies after vaccine rollout, both mRNA vaccines proved effective in preventing symptomatic and severe disease.(2-4) In clinical trials, the vaccines demonstrated 52-95% efficacy against symptomatic disease 14 days after”
BackgroundSalmanton‐García, J., Marchesi, F., da Silva, M. G., Farina, F., Dávila, J., Bilgin, Y. M., Glenthøj, A. B., Falces‐Romero, I., van Doesum, J. A., Labrador, J., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101939 · Cited by 36
Tailoring Highly Branched Poly(β-amino ester)s for Efficient and Organ-Selective mRNA Delivery
Yong, H., Lin, L., Li, Z., Guo, R., Wang, C., Liu, S., & Zhou, D. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02440 · Cited by 38
Kanabar, G., & Wilkinson, P. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-244527 · Cited by 34
Spike-specific T cells are enriched in breastmilk following SARS-CoV-2 mRNA vaccination
Armistead, B., Jiang, Y., Carlson, M., Ford, E. S., Jani, S., Houck, J., Wu, X., Jing, L., Pecor, T., Kachikis, A. B., et al. (2023) · Mucosal Immunology · doi:10.1016/j.mucimm.2023.01.003 · Cited by 34
“Time since delivery, weeks, median (range) 26 (2-56) Time since 2 SARS2 mRNA dose, weeks, median (range) 11 (0.”
Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) Vaccines
Lin, D.-Y., Zeng, D., & Gilbert, P. B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab226 · Cited by 34
Feghali, E. J., Zafar, M. G., Abid, S., Santoriello, D., & Mehta, S. P. (2021) · Cureus · doi:10.7759/cureus.19616 · Cited by 34
“Severe adverse effects are rarely reported [1-3].”
Sen, P., Ravichandran, N., Nune, A., Lilleker, J. B., Agarwal, V., Kardeş, S., Kim, M., Day, J. A., Milchert, M., Gheita, T. A., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac305 · Cited by 36
Lipid Nanoparticles Enhance mRNA Delivery to the Central Nervous System Upon Intrathecal Injection
Xue, Y., Wang, C., Li, H., Du, S., Zhong, Y., Zhang, Y., Wang, S., Guo, K., Hou, X., Kang, D. D., et al. (2025) · Advanced Materials · doi:10.1002/adma.202417097 · Cited by 34
COVID-19 in Latin America: A Snapshot in Time and the Road Ahead
LaRotta, J., Escobar, O., Avila-Aguero, M. L., Torres, J. P., de Almeida, R. S., Morales, G. D. C., & Srivastava, A. K. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00748-z · Cited by 49
“The pivotal BNT162b2 phase 2/3 study of BNT162b2 in C 16-year-olds included sites in Argentina (n = 1; 5764 participants) and Brazil (n = 2; 2284 participants) [68].”
BackgroundZhang, Y.-N., Paynter, J., Sou, C., Fourfouris, T., Wang, Y., Abraham, C., Ngo, T., Zhang, Y., He, L., & Zhu, J. (2021) · Science Advances · doi:10.1126/sciadv.abj3107 · Cited by 35
Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
Vidal, S. J., Collier, A.-R. Y., Yu, J., McMahan, K., Tostanoski, L. H., Ventura, J. D., Aïd, M., Peter, L. E., Jacob-Dolan, C., Anioke, T., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00404-21 · Cited by 34
Deulofeu, M., García-Cuesta, E., Peña‐Méndez, E. M., Conde, J. E., Jiménez-Romero, O., Verdú, E., Serrando, M., Salvadó, V., & Boadas‐Vaello, P. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.661358 · Cited by 33
Extracellular Vesicles as Drug Targets and Delivery Vehicles for Cancer Therapy
Chitti, S. V., Nedeva, C., Manickam, R., Fonseka, P., & Mathivanan, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122822 · Cited by 36
Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records
Niesen, M. J. M., Pawlowski, C., O’Horo, J. C., Challener, D. W., Silvert, E., Donadio, G., Lenehan, P. J., Virk, A., Swift, M. D., Speicher, L. L., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7038 · Cited by 35
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Heitmann, J. S., Tandler, C., Marconato, M., Nelde, A., Habibzada, T., Rittig, S. M., Tegeler, C. M., Maringer, Y., Jaeger, S. U., Denk, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40758-0 · Cited by 38
Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review
Abolmaali, M., Rezania, F., Behnagh, A. K., Hamidabad, N. M., Gorji, A., & Mirzaasgari, Z. (2022) · Immunologic Research · doi:10.1007/s12026-022-09316-6 · Cited by 38
“The Pfizer vaccine ranked second for COVID-19 vaccine–associated GBS in our study while no neurological adverse events were described in the phase III study [65].”
BackgroundNewman, P. A., Reid, L., Tepjan, S., Fantus, S., Allan, K., Nyoni, T., Guţă, A., & Williams, C. C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266120 · Cited by 45
“COVID-19 vaccine trial data [35-38], a history of unethical medical experimentation [32,39] and”
BackgroundPatrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021) · Radiology Case Reports · doi:10.1016/j.radcr.2021.07.082 · Cited by 36
“The mRNA vaccines, that encode the prefusion SARS-CoV-2 spike glycoprotein, have shown to confer a very high protection against Covid-19 with a safe profile [4-5] .”
The Immune Response to SARS-CoV-2 and Variants of Concern
Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 39
Antiplatelet drugs block platelet activation by VITT patient serum
Smith, C. W., Montague, S. J., Kardeby, C., Di, Y., Lowe, G., Lester, W., Watson, S. P., & Nicolson, P. L. R. (2021) · Blood · doi:10.1182/blood.2021012277 · Cited by 40
Kircheis, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910791 · Cited by 36
Painless idiopathic neuralgic amyotrophy after COVID ‐19 vaccination: A case report
Diaz‐Segarra, N., Edmond, A., Gilbert, C., et al. (2021) · PM&R · doi:10.1002/pmrj.12619 · Cited by 33
Brand, I., Gilberg, L., Bruger, J., Garí, M., Wieser, A., Eser, T. M., Frese, J., Ahmed, M. I. M., Rubio‐Acero, R., Noller, J. M. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.688436 · Cited by 41
“Vaccines, mostly targeting the Spike protein of SARS-CoV-2 have been developed and approved at an unprecedented pace in history based on evidence for high efficacy (1).”
BackgroundBorisova, N. I., Kotov, I. A., Kolesnikov, A. A., Kaptelova, V. V., Speranskaya, A. S., Kondrasheva, L. Y., Tivanova, E. V., Khafizov, K., & Акимкин, В. Г. (2021) · Problems of Virology · doi:10.36233/0507-4088-72 · Cited by 33
The time to offer treatments for COVID-19
Ngo, B., Marik, P. E., Kory, P. D., Shapiro, L., Thomadsen, R., Iglesias, J. I., Ditmore, S., Rendell, M., Varón, J., Dubé, M. P., et al. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1901883 · Cited by 32
Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients
Fuentes, J. D. B., Mohamed, K. M., Aguilar, A. D. L., García, C. J., Guevara‐Hoyer, K., Fernández‐Arquero, M., de la Peña, M. A. R., García-Bravo, L., Ortega, A. F. J., Navarro, P. F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975980 · Cited by 34
“Cancer patients and other immunocompromised populations were also excluded or underrepresented in the clinical trials for the SARS-CoV-2 mRNA vaccines (16, 17).”
BackgroundHigh-Throughput Automation of Endosomolytic Polymers for mRNA Delivery
Ulkoski, D., Munson, M. J., Jacobson, M. E., Palmer, C. R., Carson, C. S., Sabirsh, A., Wilson, J. T., & Krishnamurthy, V. R. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01463 · Cited by 34
Shibata, S., Kobayashi, K., Tanaka, M., Asayama, K., Yamamoto, E., Nakagami, H., Hoshide, S., Kishi, T., Matsumoto, C., Mogi, M., et al. (2022) · Hypertension Research · doi:10.1038/s41440-022-01134-5 · Cited by 38
“The overall incidence of hypertension after mRNA vaccination (mRNA-1273 and BNT162b2) was reported to be less than 1% [73, 74].”
BackgroundFàbrega, C., Aviñó, A. M., Navarro, N., Jorge, A. F., Grijalvo, S., & Eritja, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020320 · Cited by 36
“This approval facilitated the rapid authorization of the two mRNA vaccines for SARS-CoV-2 [98,99].”
BackgroundShim, E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18147578 · Cited by 35
Maiese, A., Baronti, A., Manetti, A. C., Paolo, M. D., Turillazzi, E., Frati, P., & Fineschi, V. (2022) · Vaccines · doi:10.3390/vaccines10020308 · Cited by 37
“The clinical trials performed to evaluate the safety of the COVID-19 vaccines before general administration did not highlight cases of ADEM [92,93].”
MethodInfluentialSafety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
Underwood, E., Dunkle, L. M., Madhi, S. A., Gay, C. L., Heath, P. T., Kotloff, K. L., Smith, K., Chau, G., Galbiati, S., McGarry, A., et al. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2218913 · Cited by 36
Machine learning techniques for lipid nanoparticle formulation
Li, H., Zhao, Y., & Xu, C. (2025) · Nano Convergence · doi:10.1186/s40580-025-00502-4 · Cited by 43
COVID-19: vaccines, efficacy and effects on variants
Rudan, I., Adeloye, D., & Sheikh, A. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000868 · Cited by 40
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.